Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Michigan, Michigan Medicine, University of Utah, Huntsman Cancer Institute, City Of Hope National Medical Center, Vanderbilt University Medical Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, Washington University in St. Louis, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, U-M Rogel Cancer Center, University of California, San Francisco, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2790168882